New Prospects for Small Cell Lung Cancer Patients (Part II)


Small cell lung carcinoma (SCLC) accounts for about 15% of lung cancers, but it is the deadliest form of lung malignancy. Only 6% of patients with SCLC survive beyond 5 years after diagnosis. In the last few years, new therapies—targeted therapies in particular—have been developed and approved by the U.S. Food and Drug Administration (FDA) for treating other, more common forms of lung cancer such as adenocarcinoma. However, not much progress has been made in addressing SCLC, which is usually treated with a combination of fairly toxic chemotherapeutics and radiotherapy. Many patients respond to these harsh treatments (ie, their tumors shrink), but only transiently. The disease recurs within a few months to 1 year and, at that point, is no longer treatable. Continue reading…


Antidepressant Drugs May Also Treat SCLC

Two drugs that are currently approved to treat symptoms of depression may also be effective against small cell lung cancer (SCLC). Researchers used bioinformatics, which combines mathematics and computer science to analyze large amounts of biological data, to pinpoint drugs likely to act on pathways that are important in SCLC. They identified the antidepressant imipramine (Tofranil) and the sedative/anti-nausea medication promethazine (Phenergan). Both drugs killed SCLC cells both in cell culture and in mouse models of chemotherapy-resistant SCLC. SCLC tumors arise from cells that are part of the hormone and nervous system, which may explain the effectiveness of these drugs. A new clinical trial will explore the effectiveness of desipramine (Norpramin), a drug similar to Tofranil, in SCLC.